Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Grace Therapeutics Inc. (GRCE:NASDAQ), powered by AI.
Grace Therapeutics Inc. is currently trading at $2.35. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Grace Therapeutics Inc. on Alpha Lenz.
Grace Therapeutics Inc.'s P/E ratio is -3.0.
“Grace Therapeutics Inc. trades at a P/E of -3.0 (undervalued) with modest ROE of -14.9%.”
Ask for details →Grace Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments. The company specializes in creating unique drug formulations and delivery systems to address unmet medical needs, particularly in the fields of neurology and rare diseases. Notable for its research and development efforts, Grace Therapeutics aims to enhance the effectiveness and patient experience of existing drugs by altering their formulations. This approach not only seeks to improve therapeutic outcomes but also targets a reduction in side effects and enhanced patient compliance. Headquartered in the United States, Grace Therapeutics Inc. collaborates with healthcare professionals, research institutions, and regulatory bodies to bring its innovative solutions to the market. By prioritizing innovation in drug delivery systems, the company plays a critical role in advancing medical treatments and addressing significant gaps within the pharmaceutical landscape, potentially offering new hope to patients with limited treatment options.
“Grace Therapeutics Inc. trades at a P/E of -3.0 (undervalued) with modest ROE of -14.9%.”
Ask for details →Grace Therapeutics Inc. (ticker: GRCE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 6 employees. Market cap is $28M.
The current price is $2.35 with a P/E ratio of -2.97x and P/B of 0.43x.
ROE is -14.91%.